JPWO2019178573A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019178573A5 JPWO2019178573A5 JP2020549620A JP2020549620A JPWO2019178573A5 JP WO2019178573 A5 JPWO2019178573 A5 JP WO2019178573A5 JP 2020549620 A JP2020549620 A JP 2020549620A JP 2020549620 A JP2020549620 A JP 2020549620A JP WO2019178573 A5 JPWO2019178573 A5 JP WO2019178573A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- item
- items
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 453
- 229910052727 yttrium Inorganic materials 0.000 claims description 147
- 229910052717 sulfur Inorganic materials 0.000 claims description 146
- 229910052799 carbon Inorganic materials 0.000 claims description 144
- 229910052731 fluorine Inorganic materials 0.000 claims description 144
- 229910052721 tungsten Inorganic materials 0.000 claims description 144
- 229910052757 nitrogen Inorganic materials 0.000 claims description 130
- 229910052698 phosphorus Inorganic materials 0.000 claims description 110
- 239000003814 drug Substances 0.000 claims description 81
- 229940079593 drug Drugs 0.000 claims description 77
- 150000001413 amino acids Chemical class 0.000 claims description 68
- 239000013543 active substance Substances 0.000 claims description 46
- 125000000539 amino acid group Chemical group 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000001575 pathological effect Effects 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 102000007079 Peptide Fragments Human genes 0.000 claims description 12
- 108010033276 Peptide Fragments Proteins 0.000 claims description 12
- 210000000845 cartilage Anatomy 0.000 claims description 12
- 239000002872 contrast media Substances 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 11
- 206010003246 arthritis Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- -1 desiccresonide Chemical compound 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010061481 Renal injury Diseases 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 239000004012 Tofacitinib Substances 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108050003627 Wnt Proteins 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims 1
- 229940043256 calcium pyrophosphate Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims 1
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 229960001350 tofacitinib Drugs 0.000 claims 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 55
- 238000000034 method Methods 0.000 description 42
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000032 diagnostic agent Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 102220624725 Atrial natriuretic peptide receptor 2_N24Q_mutation Human genes 0.000 description 6
- 102220606761 Gap junction beta-1 protein_N30V_mutation Human genes 0.000 description 6
- 102220624591 Kelch repeat and BTB domain-containing protein 3_T36Y_mutation Human genes 0.000 description 6
- 102220480221 Nicotinate phosphoribosyltransferase_R1K_mutation Human genes 0.000 description 6
- 102220510219 Poly(A)-specific ribonuclease PNLDC1_S31G_mutation Human genes 0.000 description 6
- 102220558444 Proteinase-activated receptor 2_N30A_mutation Human genes 0.000 description 6
- 102220558462 Proteinase-activated receptor 2_N30S_mutation Human genes 0.000 description 6
- 102220501206 Scaffold attachment factor B1_S25G_mutation Human genes 0.000 description 6
- 102220477417 Uncharacterized protein FLJ30774_R14K_mutation Human genes 0.000 description 6
- 102220209838 rs1057520382 Human genes 0.000 description 6
- 102220210869 rs1057524586 Human genes 0.000 description 6
- 102200009633 rs12263012 Human genes 0.000 description 6
- 102220288775 rs1554193610 Human genes 0.000 description 6
- 102200048328 rs1801270 Human genes 0.000 description 6
- 102220295226 rs201491900 Human genes 0.000 description 6
- 102220261991 rs372235657 Human genes 0.000 description 6
- 102220065945 rs376818200 Human genes 0.000 description 6
- 102220165274 rs61754263 Human genes 0.000 description 6
- 102220098395 rs7023652 Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- 102220175812 rs149258999 Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 208000034693 Laceration Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 229940122642 Calcium channel agonist Drugs 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical group C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229940122117 Potassium channel agonist Drugs 0.000 description 1
- 229940122075 Potassium channel antagonist Drugs 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940122616 Sodium channel agonist Drugs 0.000 description 1
- 229940089973 Sodium channel antagonist Drugs 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000000801 calcium channel stimulating agent Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012336 endoscopic ultrasonography Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000003378 sodium channel stimulating agent Substances 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023203841A JP2024015145A (ja) | 2018-03-16 | 2023-12-01 | 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644329P | 2018-03-16 | 2018-03-16 | |
| US62/644,329 | 2018-03-16 | ||
| US201862676033P | 2018-05-24 | 2018-05-24 | |
| US62/676,033 | 2018-05-24 | ||
| PCT/US2019/022630 WO2019178573A1 (en) | 2018-03-16 | 2019-03-15 | Truncated cartilage-homing peptides and peptide complexes and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023203841A Division JP2024015145A (ja) | 2018-03-16 | 2023-12-01 | 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518357A JP2021518357A (ja) | 2021-08-02 |
| JP2021518357A5 JP2021518357A5 (https=) | 2022-03-23 |
| JPWO2019178573A5 true JPWO2019178573A5 (https=) | 2022-03-23 |
Family
ID=67906952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549620A Ceased JP2021518357A (ja) | 2018-03-16 | 2019-03-15 | 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 |
| JP2023203841A Pending JP2024015145A (ja) | 2018-03-16 | 2023-12-01 | 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023203841A Pending JP2024015145A (ja) | 2018-03-16 | 2023-12-01 | 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210171589A1 (https=) |
| EP (1) | EP3773668A4 (https=) |
| JP (2) | JP2021518357A (https=) |
| CN (1) | CN112105375A (https=) |
| AU (1) | AU2019233914A1 (https=) |
| CA (1) | CA3093588A1 (https=) |
| WO (1) | WO2019178573A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4031162A1 (en) * | 2019-09-20 | 2022-07-27 | Zealand Pharma A/S | Kv1.3 blockers |
| JP2024503480A (ja) * | 2021-01-19 | 2024-01-25 | ウィリアム マーシュ ライス ユニバーシティ | ポリペプチドの骨特異的送達法 |
| CN116206697B (zh) * | 2023-01-18 | 2025-07-15 | 北京石油化工学院 | 共晶配体筛选方法和系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592009B2 (en) * | 2006-10-10 | 2009-09-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Polypeptide ligands for targeting cartilage and methods of use thereof |
| JP5463013B2 (ja) * | 2007-06-19 | 2014-04-09 | 国立大学法人 岡山大学 | 軟骨マーカー |
| CN105008393A (zh) * | 2012-12-10 | 2015-10-28 | 弗莱德哈钦森癌症研究中心 | 用于筛选的方法 |
| EP2981821B2 (en) * | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| US20170050988A1 (en) * | 2013-11-25 | 2017-02-23 | Sanofi | Dotam derivatives for therapeutic use |
| CN107405388A (zh) * | 2015-01-08 | 2017-11-28 | 衣阿华大学研究基金会 | 用于体内关节软骨再生的方法 |
| US11090358B2 (en) * | 2015-09-09 | 2021-08-17 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| AU2016366668A1 (en) * | 2015-12-11 | 2018-05-31 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
| US20190375786A1 (en) * | 2016-09-09 | 2019-12-12 | Fred Hutchinson Cancer Research Center | Stable peptides and methods of use thereof |
| EP3595699A4 (en) * | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| AU2018283161A1 (en) * | 2017-06-15 | 2020-01-02 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
-
2019
- 2019-03-15 WO PCT/US2019/022630 patent/WO2019178573A1/en not_active Ceased
- 2019-03-15 EP EP19767592.9A patent/EP3773668A4/en not_active Withdrawn
- 2019-03-15 CA CA3093588A patent/CA3093588A1/en active Pending
- 2019-03-15 AU AU2019233914A patent/AU2019233914A1/en not_active Abandoned
- 2019-03-15 CN CN201980030545.8A patent/CN112105375A/zh active Pending
- 2019-03-15 US US16/980,787 patent/US20210171589A1/en not_active Abandoned
- 2019-03-15 JP JP2020549620A patent/JP2021518357A/ja not_active Ceased
-
2023
- 2023-12-01 JP JP2023203841A patent/JP2024015145A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7378449B2 (ja) | 軟骨ホーミングペプチド | |
| Mease et al. | PET imaging in prostate cancer: focus on prostate-specific membrane antigen | |
| JP7280193B2 (ja) | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 | |
| JP2020511459A5 (https=) | ||
| JP6789823B2 (ja) | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 | |
| CN107001417A (zh) | 靶向肽及其使用方法 | |
| JP2024015145A (ja) | 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法 | |
| JP2019533693A (ja) | 抗ｄｋｋ−１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ−カテニンの使用 | |
| JP2021518357A5 (https=) | ||
| WO2022108929A1 (en) | Near infrared-ii probes as high affinity targeting imaging agents and uses thereof | |
| JP6055417B2 (ja) | 放射性トレーサー組成物 | |
| KR20220152322A (ko) | 생체내 알파-v-베타-6-인테그린 접근을 위한 환형 펩타이드 및 그의 컨쥬게이트 | |
| JP6186371B2 (ja) | 患者選別方法 | |
| JPWO2019178573A5 (https=) | ||
| AU2012324981A1 (en) | Method and unit for the processing of sunflower-extraction meal | |
| US9211349B2 (en) | Molecular probes for multimodality imaging of anionic membrane surfaces | |
| US20150352192A1 (en) | Methods and compositions for treating cancer | |
| KR20250016195A (ko) | 전립선-특이적 막 항원(psma) 리간드 | |
| US20240115744A1 (en) | Fibrin-binding compounds for imaging and treatment | |
| US11795197B2 (en) | Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery | |
| EP3999123A1 (en) | A receptor-targeting conjugate with an effective pharmacokinetic profile | |
| JP5604305B2 (ja) | 線維症の非侵襲性の特異的イメージングのための、ポリペプチド、環状ポリペプチドおよびそれを含む医薬 | |
| JP2021522172A (ja) | 軟骨ホーミングペプチドの複合体 | |
| WO2024196776A2 (en) | Developing an anti-human cd45 imaging probe for noninvasive detection of human immune cells | |
| TW202544005A (zh) | 放射性醫藥組合物及方法 |